Australia - English - Department of Health (Therapeutic Goods Administration)

arthropharm pty ltd - pentosan polysulfate sodium, quantity: 100 mg - capsule, hard - excipient ingredients: microcrystalline cellulose; magnesium stearate; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; gelatin; sodium lauryl sulfate; silicon dioxide - indications as at 5 august 2021: elmiron is indicated for the treatment of interstitial cystitis. relief of symptoms in patients with interstitial cystitis may not be experienced until 6 to 8 weeks of therapy with elmiron. continuing long-term therapy is necessary for persistent relief of symptoms. relief of symptoms may not occur in all patients, and relapse is likely to occur gradually if treatment is discontinued, even after long periods of therapy.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sykes vet (international) pty. ltd. - inisitol; calcium as calcium carbonate; cobalt as cobalt (ii) sulfate; copper as copper (ii) sulfate; iron as ferrous fumarate; biotin - vitamin h; choline bitartrate; vitamin b12 = cyanocobalamin; vitamin b3 = nicotinamide; vitamin b5; vitamin b2 = riboflavin; vitamin b1 = thiamine; vitamin b6 = pyridoxine; vitamin c = ascorbic acid; vitamin m = folic acid = pga - oral powder, pre-mix - inisitol ungrouped active 400.0 mg/30g; calcium as calcium carbonate mineral-calcium-salt active 3744.0 mg/30g; cobalt as cobalt (ii) sulfate mineral-cobalt active 325.0 ug/30g; copper as copper (ii) sulfate mineral-copper active 6.5 mg/30g; iron as ferrous fumarate mineral-iron active 400.0 mg/30g; biotin - vitamin h vitamin-b complex active 50.0 ug/30g; choline bitartrate vitamin-b complex active 1896.0 mg/30g; vitamin b12 = cyanocobalamin vitamin-b12 active 22.0 mg/30g; vitamin b3 = nicotinamide vitamin-b3 active 1000.0 mg/30g; vitamin b5 vitamin-b5 active 352.0 mg/30g; vitamin b2 = riboflavin vitamin-b2 active 295.0 mg/30g; vitamin b1 = thiamine vitamin-b1 active 1200.0 mg/30g; vitamin b6 = pyridoxine vitamin-b6 active 362.0 mg/30g; vitamin c = ascorbic acid vitamin-c active 2500.0 mg/30g; vitamin m = folic acid = pga vitamin-m active 96.0 mg/30g - nutrition & metabolism - dog - greyhound | horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | - iron & haemopoietic agent | anaemia | haemopoietic agents | hematinic | iron deficiency

Israel - English - Ministry of Health

teva israel ltd - spironolactone - tablets - spironolactone 100 mg - spironolactone - spironolactone - edematous conditions: congestive heart failure; cirrosis of the liver accompanied by edema and/or ascites nephrotic syndrome. essential hypertention. primary hyperaldostronism. hypokalemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - iron polymaltose, quantity: 370 mg (equivalent: iron, qty 100 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; macrogol 6000; crospovidone; magnesium stearate; titanium dioxide; hypromellose; hyprolose; iron oxide yellow; iron oxide red - treatment of iron deficiency in adults and adolescents where the use of ferrous iron supplements is not tolerated, or otherwise inappropriate. prevention of iron deficiency in adults and adolescents at high risk where the use of ferrous iron supplements is not tolerated, or otherwise inappropriate.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - pentosan polysulfate sodium (unii: 914032762y) (pentosan polysulfate - unii:f59p8b75r4) - pentosan polysulfate sodium 100 mg - elmiron® (pentosan polysulfate sodium) is indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. elmiron® is contraindicated in patients with known hypersensitivity to the drug, structurally related compounds, or excipients.

United States - English - NLM (National Library of Medicine)

a-s medication solutions - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg - spironolactone tablets are indicated for treatment of nyha class iii-iv heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. spironolactone tablets are usually administered in conjunction with other heart failure therapies. spironolactone tablets are indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one dru

United States - English - NLM (National Library of Medicine)

unit dose services - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg - spironolactone is indicated in the management of: primary hyperaldosteronism for: establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. short-term preoperative treatment of patients with primary hyperaldosteronism. long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). edematous conditions for patients with: congestive heart failure: for the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. spironolactone is also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. cirrhosis of the liver accompanied by edema and/or ascites: aldosterone levels may be exceptionally high in this condition. spi

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg - spironolactone tablets are indicated for treatment of nyha class iii-iv heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. spironolactone tablets are usually administered in conjunction with other heart failure therapies. spironolactone tablets are indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one dru

United States - English - NLM (National Library of Medicine)

unit dose services - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 100 mg - spironolactone is indicated in the management of: primary hyperaldosteronism for: establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. short-term preoperative treatment of patients with primary hyperaldosteronism. long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). edematous conditions for patients with: congestive heart failure: for the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. spironolactone is also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. cirrhosis of the liver accompanied by edema and/or ascites: aldosterone levels may be exceptionally high in this condition. spi

United States - English - NLM (National Library of Medicine)

northwind pharmaceuticals, llc - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg - spironolactone tablets are indicated in the management of: primary hyperaldosteronism for: establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. short-term preoperative treatment of patients with primary hyperaldosteronism. long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). edematous conditions for patients with: congestive heart failure: for the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. spironolactone tablets are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. cirrhosis of the liver accompanied by edema and/or ascites: spironolactone levels may be exceptionally high in th